MAD2 shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

MAD2 shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
MAD2 shRNA Plasmid (h)

Product Specs
ItemMAD2 shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-35837-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
NCBI Gene AliasesHSMAD2, MAD2
NCBI Full Gene Namemitotic arrest deficient 2 like 1
Specieshuman
TypeshRNA Plasmid

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) The cell cycle protein MAD2 facilitates endocytosis of the serotonin transporter in the neuronal somaEMBO reportsOctober 9, 2023Koban F, Freissmuth M.

(2) Camptothecin induces mitotic arrest through Mad2-Cdc20 complex by activating the JNK-mediated Sp1 pathwayFood and chemical toxicology : an international journal published for the British Industrial Biological Research AssociationMay 1, 2019Dilshara MG, Jayasooriya RGPT, Karunarathne WAHM, Choi YH, Kim GY.

(3) Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticlesActa biomaterialiaJanuary 1, 2017Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM.

(4) miR-128 regulates differentiation of hair follicle mesenchymal stem cells into smooth muscle cells by targeting SMAD2Acta histochemicaMay 1, 2016Wang Z, Pang L, Zhao H, Song L, Wang Y, Sun Q, Guo C, Wang B, Qin X, Pan A.

(5) Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer modelsNanomedicine (London, England)April 1, 2016Nascimento AV, Gattacceca F, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM.

(6) Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosomeMolecular and cellular biologyJanuary 1, 2015Nath S, Chowdhury A, Dey S, Roychoudhury A, Ganguly A, Bhattacharyya D, Roychoudhury S.

(7) Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer modelMolecular pharmaceuticsOctober 6, 2014Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM.

(8) Role of cyclin B1/Cdc2 in mediating Bcl-XL phosphorylation and apoptotic cell death following nocodazole-induced mitotic arrestMolecular carcinogenesisFebruary 1, 2014Choi HJ, Zhu BT.

(9) The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormalityBiochemical and biophysical research communicationsOctober 4, 2013Hitomi T, Habu T, Kobayashi H, Okuda H, Harada KH, Osafune K, Taura D, Sone M, Asaka I, Ameku T, et al.

(10) Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiolBiochimica et biophysica actaAugust 1, 2012Choi HJ, Zhu BT.

(11) Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazolePloS oneJanuary 1, 2011Choi HJ, Fukui M, Zhu BT.

(12) Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53Molecular cancer therapeuticsDecember 1, 2010Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N.

Be the First to Write a Review!